drugset / Trial / NCT04843709
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.
Timeline
- Start
- 2021-07-26
- Primary completion
- 2024-03-20
- Completion
- 2024-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MRG004A | Unknown | — | Intravenous |
Indications
No indication recorded.